ARCA biopharma's (ABIO) Gencaro Featured in Journal JACC: Heart Failure StreetInsider.com (subscription) ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper "Prevention of Atrial Fibrillation by Bucindolol is Dependent on the Beta-1 389 ... |
